Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Orthofix Medical Inc., encouraging shareholders to contact the firm to discuss their rights and options [1]. Group 1: Shareholder Rights and Legal Actions - Shareholders of Orthofix Medical Inc. are urged to reach out to Halper Sadeh LLC as there may be limited time to enforce their rights [1]. - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees [1]. - Long-term shareholders may seek corporate governance reforms, financial incentives, or other benefits through legal action [1]. Group 2: Importance of Shareholder Involvement - Shareholder participation is emphasized as a means to improve company policies and oversight, potentially enhancing shareholder value [1]. - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [1].

Core Viewpoint - Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of Orthofix Medical Inc. [1] Company Summary - Orthofix Medical Inc. is currently under scrutiny for possible fiduciary duty violations by its leadership [1]. - Shareholders of Orthofix Medical are encouraged to seek more information regarding the investigation [1].

Summary of Orthofix Medical FY Conference Call Company Overview - **Company**: Orthofix Medical (NasdaqGS: OFIX) - **Date of Conference**: March 03, 2026 - **Key Speakers**: Matt Blackman (TD Cowen), Julie Andrews (CFO), Julie Dewey Key Points Company Positioning and Transformation - Orthofix inherited a company with strong assets but a weak operating model and financial profile, which were not conducive to sustainable growth [3][4] - The company underwent significant management and portfolio overhauls, focusing on financial health and operational efficiency [2][3] - The SeaSpine merger introduced innovation but also complexity and cash burn, necessitating a reset of the business foundation [3][4] Financial Performance and Growth Strategy - The company has shifted focus towards profitable growth, optimizing capital allocation and commercial footprint [6] - Over 75% of U.S. spine sales now come from the top 30 distributors, up from less than half in early 2024, leading to improved execution and predictability [6][16] - Debt refinancing in November 2024 improved liquidity and capital access, supporting long-term growth [7] - Orthofix has achieved eight consecutive quarters of EBITDA margin expansion, moving from a cash burn of over $100 million in 2023 to nearly breakeven in 2025 [8] Future Projections - The company targets a net sales CAGR of 6.5% to 7.5% from 2026 to 2028, with an adjusted EBITDA margin in the mid-teens by 2028 [22] - The growth will be driven by capturing benefits from distributor transitions, a strong innovation pipeline, and new product launches [27][28] Product Launches and Innovation - Orthofix plans over a dozen product launches in the next 18 months, including the Verata Open and Verata MIS platforms, which are expected to drive multi-year growth [7][28] - The company is also focusing on enhancing its Limb Reconstruction business, which has a significant market opportunity of $2.6 billion [88] Market Dynamics and Competitive Position - The Bone Growth Therapy (BGT) segment holds over 50% market share in the spine segment and is positioned for further growth in the fracture market, which is valued at approximately $250 million [60][67] - The Limb Reconstruction business is expected to return to double-digit growth, supported by new product launches and a focused commercial strategy [89] Challenges and Considerations - Legal expenses related to the former leadership team are expected to decrease, which has been a headwind for free cash flow [37][41] - The company is managing a 1% headwind in Q1 due to timing of utilization, but this is not expected to affect physician prescribing behavior [75][86] Conclusion - Orthofix is positioned for significant growth driven by operational improvements, a strong innovation pipeline, and a more efficient commercial strategy [52][112] - The company believes it is fundamentally stronger than two years ago, with a favorable outlook for future performance [112]

Summary of Orthofix Conference Call Company Overview - **Company**: Orthofix - **Industry**: Medical Devices, specifically focused on orthopedic and spinal solutions Key Points and Arguments 1. **Q4 Performance**: Orthofix reported strong operational progress in Q4, demonstrating effective strategy implementation with growth in Bone Growth Therapies and U.S. Limb Reconstruction business, alongside improved performance in the spine segment [2][4] 2. **Financial Metrics**: The company achieved its eighth consecutive quarter of EBITDA margin expansion and positive free cash flow, indicating financial discipline and scalability of its business model [2][8] 3. **2026 Guidance**: The company anticipates 5.5% pro forma growth at the midpoint, with 70 basis points of adjusted EBITDA margin expansion and free cash flow positivity expected in fiscal year 2026 [4] 4. **Segment Growth Expectations**: - Bone Growth Therapies expected to grow above market rates - U.S. Limb Reconstruction projected to return to double-digit growth in the second half of the year - Spine segment expected to show improved performance throughout the year [5][6] 5. **Channel Optimization**: The company has completed distributor transitions and channel upgrades, which are expected to yield benefits in the long term, although the timeline for long-range goals has been pushed from 2027 to 2028 [10][11] 6. **Distributor Relationships**: Over 75% of business now comes from top 30 distributors, up from less than 50% in 2024, indicating successful channel consolidation [12] 7. **7D Technology**: The 7D system has seen a 30% increase in earn-out placements compared to 2024, with strong usage and attachment to other products [16] 8. **Biologics Focus**: The company is re-energizing its biologics business after experiencing softness, with internal changes and increased investment in clinical data [23] 9. **Limb Reconstruction Segment**: The segment was renamed from orthopedics to better reflect strategic focus, emphasizing high-value clinical areas such as limb preservation and complex fracture management [26] 10. **Market Opportunity**: The U.S. limb reconstruction market is viewed as a significant growth opportunity, with a total addressable market (TAM) of $2.6 billion [27] 11. **Product Launches**: Upcoming launches include the TRULOC-L Elevate product line and Fitbone bone transport, with a focus on automating procedures [28] 12. **M&A Strategy**: The company is open to tuck-in acquisitions but is currently focused on generating positive free cash flow and strengthening its balance sheet [32] 13. **Long-term Outlook**: Orthofix is positioned as a stronger company with a focus on innovation, financial discipline, and a compelling growth story for long-term shareholder value [33] Additional Important Content - The company is shifting its strategy from capital sales to an earn-out program, which may impact growth in certain areas but is expected to benefit spine fixation business [6] - The discussion around radiation exposure in operating rooms has become more prominent, aligning with the benefits provided by the 7D system [19] - The company sees opportunities beyond the spine channel, particularly in limb reconstruction, indicating a diversified approach to growth [24] This summary encapsulates the key insights and strategic directions discussed during the Orthofix conference call, highlighting the company's operational progress, financial health, and market opportunities.

Core Insights - Orthofix Medical Inc. (NASDAQ:OFIX) is recognized as one of the 12 most promising small-cap stocks by Wall Street analysts [1] - Canaccord has reduced its price target for OFIX from $24 to $20 while maintaining a Buy rating, following the company's fourth-quarter performance update and its outlook for 2026 [2] Financial Outlook - For 2026, Orthofix projects adjusted EBITDA to be between $95 million and $98 million, with expectations of positive free cash flow for the entire year, excluding any potential court settlement outcomes [3] - The company anticipates revenue contributions from the TRUELOK Elevate System, FITBONE Bone Transport, and Trochanteric Lengthening Nails, along with a full launch of VIRATA in the latter half of the year [4] Strategic Focus - Management emphasizes priorities for 2026, including enhancing commercial execution, increasing market penetration, and promoting the use of enabling technologies like 7D FLASH Navigation [3] - Other areas of concentration include simplifying the Spine commercial channel, expanding the Biologics offering, and maintaining development in Limb Reconstruction and BGT operations, which are expected to support consistent revenue growth and improved cash flow [4][5]

Performance was anchored by strong results in Bone Growth Therapies (BGT) and U.S. Limb Reconstruction, alongside double-digit growth in Global Spine Fixation. Management successfully transitioned the Spine commercial channel, with the top 30 U.S. distributor partners now driving over 75% of net sales compared to less than 50% in early 2024. The 7D FLASH navigation system continues to serve as a key differentiator, with earnout customers exceeding purchase commitments by more than 50%, validating the ...

Management repeatedly emphasized changes to the spine distributor network. Calafiore said Orthofix’s top 30 U.S. distributor partners grew net sales 25% year-over-year in Q4 and 27% on a trailing 12-month basis, which he described as validation of the channel strategy. He also said that as of Q4 2025, more than 75% of U.S. net sales were driven by the top 30 distributor partners, compared with “less than a half” at the start of 2024.Global limb reconstruction: Q4 net sales of $38.0 million , driven by 8% U. ...

Orthofix Medical (NasdaqGS:OFIX) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsJulie Andrews - CFOJulie Dewey - Chief Investor Relations and Communications OfficerMassimo Calafiore - President and CEOMathew Blackman - Managing DirectorMichaela Smith - Equity Research AssociateTom Stephan - AVPConference Call ParticipantsMike Petusky - Managing Director and Senior Research AnalystOperatorThank you. I would now like to turn the call over to Julie Dewey.Julie DeweyThank you, operator, ...

Orthofix Medical (NasdaqGS:OFIX) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsJulie Andrews - CFOJulie Dewey - Chief Investor Relations and Communications OfficerMassimo Calafiore - President and CEOMathew Blackman - Managing DirectorMichaela Smith - Equity Research AssociateTom Stephan - AVPConference Call ParticipantsMike Petusky - Managing Director and Senior Research AnalystOperatorThank you. I would now like to turn the call over to Julie Dewey.Julie DeweyThank you, operator, ...

Financial Data and Key Metrics Changes - Total global net sales in Q4 reached $218.6 million, a 3% increase supported by strong performances in Bone Growth Therapies and U.S. limb reconstruction segments [12] - Pro forma non-GAAP adjusted gross margin was 71.4%, reflecting the impact of the M6 discontinuation and productivity improvements [15] - Fourth quarter pro forma non-GAAP adjusted EBITDA was $29.2 million, or 13.4% of net sales, with year-over-year margin expansion of approximately 230 basis points [15] - Free cash flow for Q4 was exceptionally strong at $16.8 million, demonstrating the strength and scalability of the business model [15] Business Line Data and Key Metrics Changes - Global spine fixation Q4 net sales grew 10% for the year and in Q4, with U.S. spine fixation net sales growing 6% for the year and 5% for the quarter [4] - Bone Growth Therapies (BGT) net sales were $68.3 million, up 7%, significantly outperforming the market [13] - U.S. limb reconstruction sales were $38 million in Q4, driven by 8% U.S. growth [14] Market Data and Key Metrics Changes - U.S. limb reconstruction grew 8% in Q4 and 16% for the full year, driven by successful product launches [7] - The spine commercial channel optimization efforts led to a 25% year-over-year growth in net sales from the top 30 U.S. distributor partners [5] Company Strategy and Development Direction - The company has rebranded its orthopedics business as limb reconstruction, focusing on four high-value clinical categories, representing an estimated $2.6 billion market opportunity [6] - The full market release of the VIRATA Spinal Fixation System is anticipated in the second half of 2026, expected to enhance surgical efficiency and serve as a multi-year growth catalyst [6] - The company is recalibrating its three-year financial targets to fully capture the anticipated benefits of its spine commercial channel optimization [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a solid foundation for growth, driven by new product launches and improved distributor performance [11] - The company expects to deliver durable top-line growth, expanding margins, and strong free cash flow in 2026 [9] - Management highlighted the importance of disciplined execution and targeted capital deployment to create sustainable long-term shareholder value [22] Other Important Information - The company expects full-year net sales of $850 million-$860 million for 2026, representing implied pro forma constant currency year-over-year growth of approximately 5.5% [16] - Adjusted growth margins for the full year are expected to be approximately 72.5% [19] Q&A Session Summary Question: Clarification on CMS impact on BGT - Management clarified that the CMS change will have about a 1% impact in Q1 specific to BGT revenue only [31] Question: Long-range plan (LRP) and margin improvement - Management indicated that the delay in the LRP reflects the extensive work done to strengthen the foundation and optimize the distributor transition [32][33] - They emphasized the focus on gross margin expansion and productivity improvements to achieve mid-teens EBITDA and positive free cash flow [35] Question: 2026 revenue guidance specifics - Management expects above-market growth for BGT and limb reconstruction, with U.S. limb reconstruction returning to double-digit growth in the second half of 2026 [40] Question: 7D placements and biologics portfolio - Management reported a 30% increase in 7D placements in 2025 and expressed confidence in the biologics portfolio's potential for recovery and growth [48][50] Question: Tariff impact and legal settlements - Management confirmed that the tariff impact is included in the 2026 guidance, expecting about $1 million-$2 million impact [54] - They acknowledged having taken an accrual for a legal settlement in Q3 [56]